Michigan Administrative Code
Department - Licensing and Regulatory Affairs
Bureau of Professional Licensing
Board of Optometry
Board of Optometry - General Rules
Part 1 - GENERAL PROVISIONS
Section R. 338.301 - Definitions

(a) "AAO" means the American Academy of Optometry.

(b) "ACOE" means the Accreditation Council on Optometric Education.

(c) "Adverse drug reaction" means an adverse physical or psychological reaction experienced by an individual resulting from a diagnostic therapeutic agent administered by an optometrist that occurs within 24 hours after the therapeutic agent was administered. An adverse drug reaction includes any of the following:

(d) "AOA" means the American Optometric Association.

(e) "Board" means the Michigan board of optometry.

(f) "Classroom hour," for the purpose of determining whether a course of study meets the requirements of section 17412(2)(a) or 17435(2)(b) of the code, MCL 333.17412 and 333.17435, means a 50 to 60 minute period of lecture, group discussion, or laboratory directly associated with a course in pharmacology. Time spent working in a clinic other than as part of a laboratory directly associated with a course in pharmacology does not qualify as a "classroom hour."

(g) "Code" means the public health code, 1978 PA 368, MCL 333.1101 to 333.25211.

(h) "COPE" means the Council on Optometric Practitioner Education.

(i) "Course of study in general and clinical pharmacology" means a course of study that is completed in a board-approved school or college, in general and clinical pharmacology as it relates to optometry, with the characteristics described in section 17412(2)(a) of the code, MCL 333.17412. Not less than 30 of the 60 classroom hours of the course of study must be allocated to ocular pharmacology and must emphasize the systemic effects of, and reactions to, topical ocular diagnostic pharmaceutical agents, including the emergency management and referral of any adverse reactions that may occur.

(j) "Course of study relating to the didactic and clinical use of therapeutic pharmaceutical agents" means a course of study that is comprised of a minimum of 10 quarter hours or 7 semester hours of credit or 100 classroom hours of study, is completed in a board-approved school or college, and is in subjects relating to the didactic and clinical use of therapeutic pharmaceutical agents related to optometry.

(k) "CPDO" means the Continued Professional Development in Optometry.

(l) "CPR" means cardiopulmonary resuscitation.

(m) "Department" means the department of licensing and regulatory affairs.

(n) "Established patient" means an individual who has received a professional service from a provider within the optometrist's practice group within the preceding 3 years and 1 day.

(o) "Informed consent for an established patient" means consent by a patient or a patient's legal representative for treatment, medication, or services after there has been full disclosure of the facts needed for the patient or the patient's legal representative to make a voluntary decision based on the elements of knowledge, comprehension, and willingness to receive the treatment, medication, or service.

(p) "Informed consent for a new patient" means a written agreement or documentation of a verbal agreement by a patient or a patient's legal representative for treatment, medication, or services after there has been full disclosure of the facts needed for the patient or the patient's legal representative to make a voluntary decision based on the elements of knowledge, comprehension, and willingness to receive the treatment, medication, or service.

(q) "MOA" means the Michigan Optometric Association.

(r) "NBEO" means the National Board of Examiners in Optometry.

(s) "New patient" means a patient who has not received a professional service from a provider in the optometrist's practice group within the preceding 3 years and 1 day.

(t) "TMOD" means Treatment and Management of Ocular Disease.